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ABSTRACT 
Mycobacterium tuberculosis has caused tuberculosis (TB) in humans for at least 3 millennia, but the disease has evaded 
eradication efforts by all human civilisations despite promising technological advancements. The World Health Organization 
(WHO) has set a target of ending the TB epidemic by 2035. Going by the current rate of progress, it is estimated that it will 
take another 160 years to realise the WHO End TB Strategy’s target. Accelerating the eradication of TB will require effective 
tools for diagnosis, vaccines and medicines to treat the disease, and efficient implementation thereof. This presents a great 
opportunity for innovators in East Africa and the world over to chip in and develop the best technologies to end TB. With 
funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), partnerships between the UK-based 
University of St Andrews and research institutions in East and Southern Africa have led to the development of the first ever 
test – the molecular bacterial load assay (MBLA) – that measures the number of TB bacteria in a patient and reveals if this 
number is declining as a patient progresses on treatment. Initial assay results are available within 4 hours. Real-time knowl-
edge of patient mycobacterial burden and the effectiveness of prescribed medications are crucial for timely clinical decisions 
on patient management.
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INTRODUCTION
Mycobacterium tuberculosis has caused tuberculosis (TB) in humans for at least 3 millennia, but the dis-
ease has evaded eradication efforts by all human civili-
sations despite promising technological advancements. 
The disease is transmitted via the inhalation of aerosols 
laden with TB bacilli, expelled when infected individu-
als cough. One-third of the world’s population is latently 
infected with TB, reflecting one of the largest reservoirs 
of disease through asymptomatic carriers, from which 
an unfortunate 5% of cases progress to active disease.1 
Close to 10 million new cases and over 1 million TB-re-
lated deaths were reported in 2017.2 Although TB is a 
global disease, the burden varies greatly between high- 
and low- income countries. Asia and Africa, which host 
the most low- and middle-income countries (LMICs), 
account for the highest burden of TB.2 According to the 
World Health Organization (WHO), 30 countries are cat-
egorised as high–TB-burden countries (HBCs) and ac-
count for 87% of the global TB burden. Seventeen (56%) 
of the HBCs are in Africa, of which 8 (47%) are in eastern 
and southern Africa.3 Countries from the eastern–south-
ern African HBC block (ES)4 are recognised as having the 
highest burden of multidrug-resistant TB.1-3 The need for 
these countries to invest in developing effective tools to 
solve the TB problem cannot be overemphasised.
The WHO has set a target of ending the TB epidemic 
by 2035.4 Going by the current rate of progress, it is es-
timated that it will take another 160 years to realise the 
WHO End TB Strategy’s target.5 Accelerating the eradica-
tion of TB will require effective tools for diagnosis, vac-
cine and medicines to treat the disease, and efficient im-
plementation thereof. This presents a great opportunity 
for innovators in ES and the world over to chip in and 
develop the best technologies to end TB. With funding 
from the European and Developing Countries Clinical 
Trials Partnership (EDCTP), partnerships between the 
UK-based University of St Andrews and research institu-
tions in ES have led to the development of the first ever 
test – the molecular bacterial load assay (MBLA) – that 
measures the number of TB bacteria in a patient and re-
veals if this number is declining as a patient progresses 
on treatment.6,7Assay results are available at the labora-
tory within 4 hours of sample receipt. Real-time knowl-
Rapid Test for Measuring Individual TB Bacterial Load www.eahealth.org
East Africa Science 2019 | Volume 1 | Number 1 2
edge of patient mycobacterial burden and the effectiveness 
of prescribed medications are crucial for timely clinical deci-
sions on patient management.
This is a great improvement over the tools currently used 
for TB diagnosis and treatment monitoring. The gold standard 
test – M. tuberculosis culture – takes weeks or months to deliv-
er results, which is too slow to inform patient management. 
Furthermore, culture is acutely sensitive to endogenous and 
exogenous contaminants, such as non-TB bacteria and fungi, 
which grow rapidly and cause false-positive time to culture 
positivity (TTP) results.8,9 Consequently, a result from culture 
requires 3 extra confirmatory tests: (1) acid-fast microscopy 
to confirm acid-fast bacilli, (2) blood agar culture to rule out 
contamination, and (3) an antigen test, MPT64, to confirm the 
presence of M. tuberculosis. These extra tests consume more 
person-hours and increase the total cost associated with cul-
turing. Smear microscopy, which is widely available and less 
expensive, is less sensitive and cannot distinguish between 
live and dead bacteria.10 This limits the utility of smear mi-
croscopy when it comes to low-burden TB patients, such as 
children and people living with HIV, and makes it a poor tool 
for monitoring treatment responses. MBLA, therefore, is a 
technological solution to these challenges drawing on recent 
advances in molecular biology.
THE MBLA TEST
The MBLA test is specific to TB, and it has a faster turnaround 
time (TAT) than culture, taking only 24 hours for results to be 
received at the clinic. It is a reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR) assay that uses 16S-rR-
NA as a marker to detect and quantify the load of viable M. 
tuberculosis bacteria in a patient’s sputum sample. The pro-
cess starts with RNA isolation from M. tuberculosis bacteria, 
followed by RT-qPCR to quantify the RNA, then conversion of 
the RT-qPCR output (cycle threshold [CT] values) into bacte-
rial load values (estimated colony forming units per millilitre 
[eCFU/ml]) using a standard curve (Figure 1).
Unlike DNA, which can persist long after cells have died, 
RNA degrades following cell death, implying that the RNA 
measured by MBLA is from viable cells. The principle is that 
for patients responding to treatment, the number of viable M. 
tuberculosis bacilli remaining following treatment should be 
fewer than before treatment, and this number should contin-
ue declining until there is zero (undetectable) mycobacterial 
load. Changes in mycobacterial load can be detected as early 
as the third day of treatment follow-up. This means that drug 
resistance or nonadherence to treatment can be detected ear-
lier and appropriate measures can be taken. The EDCTP-fund-
ed Pan-African Biomarker Expansion (PANBIOME) study 
– conducted in Malawi, Mozambique, and Tanzania – demon-
strated that patients, on average, clear 1log10eCFU/ml of M. 
tuberculosis bacteria per week of treatment (Figure 2).
TAKING THE MBLA INTO POLICY AND PRACTICE
Many tools are invented but are never implemented in prac-
tice or are too expensive to be accessed by the majority. The 
other challenge with new technologies is their frequent in-
compatibility with existing infrastructure or environmen-
tal conditions in the target areas of implementation. Taking 
MBLA to policy and practice refers to all processes – includ-
ing technical optimisation and validation, assessment of ap-
propriateness, acceptability and cost-effectiveness – that are 
required for the tool to be adopted for the routine clinical 
management of TB. After a stakeholders conference, the WHO 
identified MBLA as having the potential to replace smear mi-
croscopy and culture for monitoring TB treatment responses.2 
Importantly, the development of MBLA has taken a co-devel-
opment model with stakeholders to ensure that the capacities 
needed to sustain the test at sites of implementation are de-
veloped in advance.
The first trial that demonstrated MBLA as a culture-free 
biomarker test for rapidly measuring patient mycobacterial 
load was conducted at South Africa’s Stellenbosch Universi-
ty. This study also demonstrated that the reduction in my-
cobacterial load measured by MBLA was consistent with the 
increase in TTP measured by automated TB liquid culture, 
Mycobacterium Growth Indicator Tube (MGIT).11 The differ-
ence between the 2 technologies is that MBLA is quantita-
tive, contamination-free, and produces results within hours, 
compared with 5 to 42 days for MGIT. A second study, con-
ducted at Tanzania’s National Institute for Medical Research 
(NIMR)–Mbeya Medical Research Centre, revealed superi-
or performance of MBLA over solid TB culture in quantify-
ing mycobacterial load and the assay results TAT.12 Funded 
by the EDCTP, the first multi-site evaluation of the test was 
conducted at the University of Malawi College of Medicine, 
Instituto Nacional de Saude, Kilimanjaro Clinical Research 
Institute, and NIMR–Mbeya Medical Research Centre in Ma-
lawi, Mozambique, and Tanzania, respectively.6 The study 
revealed that MBLA results are reproducible in different lab-
oratory settings and that it is superior to existing tools for 
the long-term follow-up of TB patients and monitoring treat-
ment response (Figure 2). Unlike culture, wherein reported 
contamination rates were as high as 30% in some settings, 
MBLA was found to be unsusceptible to contamination and 
inhibition.13 Further trials are ongoing in Uganda, Tanzania, 
Vietnam, Thailand, and the UK. The Pan African Consortium 
for the Evaluation of Antituberculosis Antibiotics (PanACEA) 
has adopted MBLA as a primary test in their clinical trials at 
over 10 sites in East and Southern Africa, as well as Gabon in 
Central Africa.
With support from the Global Challenges Research Fund 
(GCRF) and the Scottish Funding Council (SCF), the first-ever 
MBLA stakeholders conference was held at the University of 
St Andrews from 11 to 13 June 2018. Directors of national TB 
control programmes, laboratory scientists, academics, and in-
dustrialists representing 16 countries and WHO participated 
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in the conference (Figure 3). Seventeen delegates participated 
in the 2-day MBLA training session, among whom 41% were 
from East and Southern Africa (Figure 4). WHO was repre-
sented by the Laboratories, Diagnostics, and Drug Resistance 
Unit of the Global TB Programme. The conference discussed 
ways by which the MBLA test can be translated into routine 
clinical practice and accessed by the TB patients who need it 
the most. The conference underscored what the development 
of TB diagnostics should focus on – tests that identify true TB 
infections, monitoring the effectiveness of treatment, and de-
termining cure. In addition to the current evidence, the con-
ference unanimously recommended a large-scale, multisite, 
multinational, near–routine-practice evaluation of MBLA to 
conclusively answer technical and operational questions re-
quired by WHO to approve the test for routine practice. This 
work will answer questions about MBLA test sensitivity and 
specificity, sample type and frequency of testing, reproduc-
ibility, appropriateness, acceptability, and cost-effectiveness 
in relation to the current standard of care tests for TB diagno-
sis and treatment monitoring.
While commonly applied in viral disease management, 
the molecular measurement of pathogen load (the number 
of microbes causing the disease) is new in bacteriology. As 
with other bacteria, the measurement of TB bacterial load has 
depended on the laboratory cultivation of sputum (and oth-
er patient samples) in culture media to count M. tuberculosis 
colonies or determine TTP as an index of mycobacterial load. 
Unfortunately, M. tuberculosis takes weeks to grow, and this is 
too long for results to inform initial patient management de-
cisions.8 Discovered 136 years ago, and despite its shortcom-
ings of low sensitivity and inability to distinguish between 
dead and viable bacteria, semiquantitative smear microsco-
py remains the most widely used test for TB diagnosis and 
treatment monitoring.10 Microscopy is often unreliable for 
samples from children and HIV-positive patients who often 
have a low TB bacterial load. Additionally, because of its low 
sensitivity, smear microscopy is often negative a few weeks 
into treatment when patients still have a significant myco-
bacterial load.14
FIGURE 1. Diagrammatic Representation of the Molecular Bacterial Load Assay (MBLA) Process
The MBLA process begins with RNA extraction from patient sputum, followed by a reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) assay, and 
finally conversion (using qPCR analysis software [Qiagen, UK]) of the PCR output (cycle threshold [CT] values) into bacterial load values (estimated colony forming 
units per millilitre [eCFU/ml]) using a standard curve.
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FIGURE 2. Treatment Response Curves of Tuberculosis Patients Followed for 12 Weeks of Treatment
Mycobacterial load was measured at baseline before the initiation of antituberculosis therapy and weekly during treatment. Each curve represents a patient. The red 
curve demonstrates the biphasic decline in mycobacterial load as patients responded to treatment. Note the steeper slope (fast rate of sputum clearance) in the first 
2 weeks of treatment, and then a plateauing curve (slow rate of sputum clearance) in the later weeks of treatment.
FIGURE 3. The Molecular Bacterial Load Assay (MBLA) Stakeholders Conference Delegates
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THE TB CONTROL COMMUNITY SHOULD ACCELERATE 
IMPLEMENTATION
Like slow-growing M. tuberculosis colonies, the uptake of TB 
diagnostic and therapeutic innovation has been disappoint-
ingly slow. After the discovery of M. tuberculosis bacilli us-
ing a rudimentary microscope in 1880, it took 127 years to 
adopt the use of light-emitting diode (LED) technologies for 
microscopy and for the first molecular diagnostic tool – the 
line probe assay – to be adopted.15 The Xpert MTB/RIF, a rapid 
test that provides TB diagnostic results within 2 hours, was 
adopted in the 128th year. In contrast, within 10 years of de-
scribing HIV disease, viral load measurement for monitoring 
the response to antiretroviral therapy was adopted in clinical 
practice.16 After 136 years, the microscope remains the only 
WHO-approved tool for the routine monitoring of TB treat-
ment, and there is still no effective rapid test to measure my-
cobacterial load and monitor treatment responses in routine 
practice. The MBLA has been developed to fill this gap and 
ensure the early identification and appropriate management 
of patients responding poorly to treatment. With MBLA, cli-
nicians can undertake early investigations of adherence and 
drug resistance when the patient’s bacterial load does not de-
cline following the initiation of therapy. 
CONCLUSION
Through partnerships with local and international technol-
ogy developers, East Africa will leverage its capacity for bio-
medical innovation. In some respects, there is no need to rein-
vent the wheel when it comes to technologies that are already 
available. Frugal innovation, using existing knowledge and 
technology is the way to go; this way, existing technologies 
can be customised and repackaged for similar functions or 
repurposed to serve different functions of interest at afford-
able costs. It is important to note, however, that innovation 
and entrepreneurship do not happen in a vacuum. Without 
a conducive environment and financial resources, innovative 
ideas can only go so far. Governments in East Africa and Afri-
ca at large should take it upon themselves to create business 
incubation centres to nurture ideas from young entrepre-
neurs and policy frameworks to protect intellectual property 
rights, assuring innovators and their funders of good returns 
on their investments.
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